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Abstract
BACKGROUND: Targeted therapies achieved great success in managing breast cancer, however, triple negative 
breast cancers (TNBCs) lack the expression of traditional therapeutic targets, and other subtypes develop resistance 
to current therapies. The c-MET receptor emerged as a potential target with well documented pro-proliferative pro-
motility downstream signals and wide network of crosstalk with other effectors. Some reports describe a preferential 
expression of c-MET in TNBCs and promising results in early anti-c-MET clinical trials. However, the main cause of 
failure of these trials was attributed to patient selection.
AIM: The objectives of the study were to assessment of c-MET in subtypes of breast cancer and its association with 
other clinicopathological variables that may predict its expression and possibly establish other rationales to refine 
patient selection for clinical trials.
MATERIALS AND METHODS: Retrospective immunohistochemical study assessing c-MET (clone SP44) in 55 
cases of breast carcinoma. The expression of c-MET> 5% was considered positive.
RESULTS: c-MET was detected in 42% of cases. A statistically significant association of c-MET with extremes of 
age, advanced prognostic stage, carcinoma with medullary features, and high tumor infiltrating lymphocytes (TILs) 
was observed for the first time in our study. Grade III, hormone receptor negativity and TNBCs were also significantly 
associated with c-MET. Only negative progesterone receptor (PR) and high TILs were independently associated with 
c-MET in a multivariate analysis (p < 0.05). No significant association between c-MET and multifocality, size, node 
status, anatomic stage, lymphovascular or perineural invasion, and Ki-67 expression.
CONCLUSION: PR negativity and high TILs might be useful c-MET predictors and selection tools for clinical trials 
but further studies are needed to validate the unprecedented findings which may not only aid in patient selection but 
may also inspire new paradigms in future studies.
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Introduction
Breast cancer is the second most common 
cancer in general and the most common female cancer 
accounting for a major cause of death among women [1].
Although great advances in targeted anti-
human epidermal growth factor-2 (HER-2) receptor 
and hormonal therapies have ameliorated the general 
outcome for many types of breast cancer, various 
resistance mechanisms were later discovered [2].
Moreover, triple negative breast cancer 
(TNBC) is a subtype of breast cancer that essentially by 
definition lacks the expression of traditional therapeutic 
targets – namely, estrogen receptor (ER), progesterone 
receptor (PR), and HER-2 – and exhibits aggressive 
clinical course and the poorest survival of all breast 
cancers [3].
The above challenges called for investigating 
more therapeutic targets and the c-MET (mesenchymal 
epithelial transition) transmembrane surface growth 
factor receptor stood out as a potential target with a 
well-documented downstream signaling cascade 
triggering cell cycle progression, cell proliferation, 
motility, invasion, and survival culminating in an overall 
“invasive growth pattern” [4].
In the breast, c-MET is differentially 
overexpressed in carcinomatous cells as compared with 
benign tissues, making it a very attractive candidate for 
targeted therapy [5].
In addition, the c-MET receptor has a rich 
network of crosstalk with other growth factor receptors, 
especially the epidermal growth factor receptor family of 
receptors (including HER-2) and c-MET signaling was 
shown to contribute to resistance to many growth factor 
receptor-blocking therapies. Thus, c-MET antagonists 
may improve outcomes when used in combination 
with other growth factor inhibitors in targeted therapy 
strategies [6].
Regarding TNBCs, while some reports 
demonstrated a preferentially higher rate of c-MET 
expression in TNBCs [7], conflicting data were also 
presented [8]. Nevertheless, the most pronounced 
clinical benefit of c-MET blocking agents in breast 
cancers in early clinical trials was present in TNBC 
patients [9].
The main issue behind the failure of these 
trials has been related to patient selection, that is, the 
Figure 1: Non-small cell carcinoma of the lung positive control for 
c-MET expression (×200 original magnification)
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identification of effective pathological features and 
biomarkers to select those patients who are likely to 
derive most benefit from targeted c-MET inhibition 
allowing for the optimization of outcomes and minimizing 
unnecessary toxicity exposure [10].
In this study, we explored the expression of 
c-MET in immunohistochemical surrogates of molecular 
subtypes of breast cancer and its association with 
other clinicopathological variables that may predict its 
expression and possibly establish other rationales to 
refine patient selection for clinical trials.
Materials and Methods
Retrieval of cases
The material of this cross-sectional study 
was collected as 55 formalin-fixed paraffin embedded 
breast carcinoma tissue sections from archives of 
Pathology Department, Kasr AL-Ainy (Cairo University 
hospital) and private laboratories in the period between 
January 2015 and June 2017. The authors obtained 
the approval of the Ethical Committee in the Faculty of 
Medicine, Cairo University.
Inclusion criteria included cases of primary 
breast carcinomas that underwent a modified radical 
mastectomy or conservative breast surgery with or 
without axillary clearance. Exclusion criteria included 
cases with missing data (age of patients at presentation, 
tumor multifocality, tumor size (T), hormone receptor 
status, and HER-2 status), exhausted, poorly fixed or 
unavailable tissue blocks, and tru-cut biopsies.
Histopathological examination
Histopathological examination of H and E 
stained slides was performed for the confirmation of 
diagnosis of tumor histotype according to the 2012 
WHO Classification of Tumors of the Breast [11].
Tumor histological grading for invasive duct 
carcinoma was confirmed according to the Nottingham 
Grading System [12]. The grading of other types was 
based mainly on the nuclear pleomorphism and mitotic 
activity [13].
 The minimum criteria for perineural invasion 
diagnosis were the observation of cytologically 
malignant cells in the perineural space of nerves and 
in equivocal cases, the observation of total or near-total 
circumferential involvement was considered [14].
Lymphovascular invasion was defined as the 
presence of emboli of tumor cells within an endothelial 
lined space (lymphatic and/or blood vessel) outside the 
border of the tumor and/or presence of an artery or vein 
accompanying the involved vessel, and ensuring that 
the outline of the tumor cell aggregate does not exactly 
conform to the shape of the space in which it lies [15], [16].
Regarding the tumor infiltrating lymphocytes 
(TILs), they were scored following the recommendations 
of the International TILs Working Group 2014 [17]. We 
scored stromal TILs subjectively in 10% increments 
and tumors were defined as High-TILs (≥30%) or Low-
TILs (<30%) [18], [19].
Staging and molecular subtyping basis
Tumors staging was performed using the TNM 
staging system. The cases were further divided into 
anatomic stages and prognostic stage groups according 
to the latest edition of the American Joint Committee for 
Cancer (AJCC) staging manual [20].
ER, PR, HER-2, and Ki-67 status were retrieved 
from immunohistochemistry reports. ER, and PR-positive 
nuclear staining in ≥1% of tumor cells were considered 
positive according to the American Society of Clinical 
Oncology/College of American Pathologists guidelines 
recommendations [21]. HER-2 status was assessed 
according to Wolff et al., 2014 criteria [22]. Ki-67 status 
was retrieved for 29 cases only and a proliferation 
index ≥20 was considered high [23].
Regarding the molecular subtyping, the tumors 
were classified according to the St. Gallen International 
Expert Consensus 2013 recommendations and 
St. Gallen International Expert Consensus 2017 
recommendations [24], [25].
C-MET immunohistochemical staining and 
evaluation
Immunohistochemical staining for c-MET 
(clone SP44, Ventana Medical Systems) was carried 
out using rabbit monoclonal antibody directed against 
c-MET membranous and/or cytoplasmic epitope. Fully 
automated staining was carried out on the BenchMark 
XT platform from Ventana utilizing the iVIEW DAB 
detection kit using a section of non-small cell lung 
carcinoma as positive control (Figure 1).
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Immunoreactivity for c-MET was observed as 
cytoplasmic and/or membrane staining in carcinoma 
cells using literature suggested criteria: A sample was 
considered c-MET positive if >5% of definitive tumor 
cells showed immunohistochemical reactivity on the 
cell cytoplasm [26], [27].
Statistical analysis
We have investigated the association of c-MET 
expression with the age of patients at presentation, 
tumor multifocality, tumor size (T), lymph node status (N), 
AJCC anatomic and prognostic stage groups, histotype, 
histological grade, TILs, lymphovascular and perineural 
invasion, hormone receptor status, HER-2 status, Ki-67 
expression, and immunohistochemical surrogates of 
molecular subtypes. Data were coded and entered 
using the statistical package SPSS (Statistical Package 
for the Social Sciences) version 25. Simple descriptive 
statistics (arithmetic mean and standard deviation) 
were used for quantitative data while frequency (count) 
and relative frequency (percentage) were used for 
categorical data. For comparing categorical data, Chi-
square (χ2) test was performed. Exact test was used 
instead when the expected frequency is <5. Logistic 
regression multivariate analysis was done to detect 
independent predictors of c-MET expression. p < 0.05 
is considered statistically significant and p < 0.01 is 
considered statistically highly significant.
Results
This study included 55 cases of breast carcinoma. 
The age of them ranged from 22 to 86 years with a mean 
of 56.87 ± 12.76 years. Multifocal tumor masses were 
detected in n = 11, 20%. The majority of cases 74.55% 
were classified as T2, while T1 and T3 accounted for 
12.73% of cases each. In about half of the selected 
cases (51%), the detected lymph nodes were free of 
tumor deposits and N1 was the most common among 
node-positive tumors accounting for 25.4% of studied 
cases. The anatomic stage main group distribution was 
as follows: 9.1% of cases were Stage I, 63.64% were 
Stage II, and 20% were Stage III. Cases with unverified 
lymph node status were not classified. According to the 
AJCC prognostic staging classification, 30.91% of cases 
were Stage I, 40% of cases were Stage II, and 21.89% of 
cases were Stage III while 7.27% were unclassified. A total 
of 24 cases were reclassified according to this prognostic 
approach, with 14 downstaged cases (25.45%) and ten 
upstaged cases (18.18%).
The tumor histological subtypes were as 
follows; invasive duct carcinoma of no special type (NST) 
(n = 42, 76%), and carcinoma with medullary features 
(n = 9, 16%), lobular carcinoma including a single case of 
pleomorphic lobular carcinoma (n = 2, 4%), and invasive 
papillary carcinoma and cribriform carcinoma (n = 1, 2%) 
each (Figure 2).
Figure 2: (a) Invasive duct carcinoma no special type, (H and E ×100 
original magnification). (b) Invasive lobular carcinoma (H and E ×100 
original magnification). (c) Carcinoma with medullary features (H and 
E ×40 original magnification). (d) Cribriform carcinoma (H and E ×200 
original magnification). (e) Invasive papillary carcinoma no special 
type (H and E ×200 original magnification)
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Most of the studied cases were Grade II 
(n = 43, 78%) and the rest were Grade III (n = 12, 22%). A 
high rate of TILs was observed in (n = 10, 18%). Tumor-
associated lymphovascular invasion was detected 
in n = 15, 27%. Evidence of perineural invasion was 
detected in n = 5, 9% (Figure 3).
Figure 3: (a) Carcinoma with medullary features, high tumor 
infiltrating lymphocytes (H and E ×200 original magnification). 
(b) Lymphovascular invasion (H and E ×100 original magnification). 
(c) Perineural invasion (H and E ×400 original magnification)
cba
Positive ER expression was detected in n = 24, 
43.64%, positive PR expression in n = 20, 36.36%, and 
positive HER-2 in n = 1, 1.8%. Ki-67 expression was 
retrieved for only 29 cases, 11 of which (37.93%) showed 
high Ki-67 expression. The TNBCs accounted for 54.6% 
of studied cases and luminal A was the most common 
subtype in the non-triple negative group accounting 
for 29%, luminal B HER-2 negative represented 
14.55% of cases, and a single HER-2 positive case was 
encountered accounting for 1.8%.
The expression of c-MET was detected in 
23 cases (42%) (Figure 4).
The TNBCs were associated with the highest 
rate of positive c-MET expression versus other molecular 
subtypes (luminal A and B HER2 negative), while the 
luminal A subtype showed the highest rate of negative 
c-MET expression versus other molecular subtypes 
(luminal B HER-2 negative and triple negative) and these 
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Figure 4: Positive c-MET expression with varying intensities (a) weak 
c-MET expression (×400 original magnification), (b) moderate c-MET 
expression (×400 original magnification), (c) strong c-MET expression 
(×100 original magnification) 
cba
two relations were statistically significant (p = 0.003) 
and (p = 0.026), respectively. All tumors at extremes of 
age at presentation (<30 and >80 years) were c-MET 
positive and this relation was statistically significant (p 
= 0.026).
There was also a higher rate of statistically 
significant positive c-MET expression in tumors with 
advanced prognostic stage groups (p = 0.001) and 
despite that higher rates of positive c-MET expression 
were also found in advanced anatomic stage tumors, the 
later relation failed to demonstrate statistical significance 
(p = 0.612). A higher rate of positive c-MET expression 
was detected in carcinoma with medullary features 
versus other tumor histotypes and this difference was 
statistically significant (p = 0.026). A highly statistically 
significant association between positive c-MET 
expression and Grade III tumors (p < 0.001), high TILs 
(p = 0.001), ER negative status (p = 0.001), and PR 
negative status (p < 0.001) was also noticed.
There were no significant differences in c-MET 
expression regarding tumor multifocality (p = 0.097), 
T status (p = 0.901), lymph node status N (p = 0.522), 
perineural invasion (p = 0.387), lymphovascular emboli 
(p = 0.867), HER-2 status (p = 0.418), Ki 67 (p = 0.717), 
and luminal B HER-2 negative subtype (p = 0.120).
Details of the relation of c-MET expression 
with clinicopathological variables of studied cases are 
summarized in Table 1.
Multivariate analysis
Logistic regression was done to detect 
independent predictors of c-MET and exclude possible 
confounders, we found that the only independent 
predictors of c-MET expression were high TILs and PR 
negative status and all other variables were excluded 
by forward conditional regression (Table 2).
Table 2: Independent predictors of c-MET expression
c-MET B S.E. Df p-value OR 95%CI
Lower Upper
Lymphocytic infiltrate 2.197 1.130 1 0.05* 9.000 0.982 82.496
PR status −2.773- 1.109 1 0.012* 0.063 0.007 0.549
B: Unstandardized coefficient, SE: Standard error, df: Degree of freedom, OR: Odds ratio, CI: Confidence 
interval, PR: Progesterone receptor.
Discussion
In this study, we investigated c-MET expression 
in various breast carcinoma immunohistochemical profiles 
and the association of c-MET expression with the other 
pathological variables. Expression of c-MET was detected 
in 42% of the cases in this study. Similar percent (41.8%) 
was found using the same clone of monoclonal antibody 
(SP44, Ventana Systems) [28]. Lower rates as much as 
3% and 12% were found by using the same clone with a 
higher positive cutoff value (>50% tumor area) to assess 
marker “over” expression [8], [9]. A higher rate (about 69%) 
was detected using a polyclonal antibody and a low cutoff 
value (5% of tumor cells) to detect c-MET expression [27].
Table 1: Relation of c-MET expression with clinicopathological 
variables
Pathological characteristics c-MET 
positive (%)
c-MET 
negative (%)
p-value
Age
Extremes (<30 and >80 years) 4 (100) 0 (0) 0.026*
Other cases 19 (37.3) 32 (62.7)
Multifocality
Present 2 (18.2) 9 (81.8) 0.097
Absent 21 (47.7) 23 (52.3)
T status
T1 2 (28.6) 5 (71.4) 0.901
T2 18 (43.9) 23 (56.1)
T3 3 (42.9) 4 (57.1)
Node metastasis
Absent 11 (39.3) 17 (60.7) 0.54
Present 11 (47.8) 12 (52.2)
N status
N0 11 (39.3) 17 (60.7) 0.522
N1 8 (57.1) 6 (42.9)
N2 1 (20) 4 (80)
N3 2 (50) 2 (50)
Main anatomic stage groups
I 1 (20) 4 (80) 0.612
II 16 (45.7) 19 (54.3)
III 5 (45.5) 6 (54.5)
Main prognostic stage groups
I 1 (5.9) 16 (94.1) 0.001*
II 14 (63.3) 8 (36.4)
III 7 (58.3) 5 (41.7)
Histotype
Carcinoma with medullary features 7 (77.8) 2 (22.2) 0.026*
Other histotypes 16 (34.8) 30 (65.2)
Invasive duct, NST 16 (38.1) 26 (61.9) 0.314
Other histotypes 7 (53.8) 6 (46.2)
Histological grade
I 0 (0) 0 (0) <0.001*
II 12 (28.6) 30 (71.4)
III 11 (84.6) 2 (15.4)
TILs
High 9 (90) 1 (10) 0.001*
Low 14 (31.1) 31 (68.9)
Perineural invasion
Present 1 (20) 4 (80) 0.387
Absent 22 (44) 28 (56)
Lymphovascular invasion
Present 6 (40) 9 (60) 0.867
Absent 17 (42.5) 23 (57.5)
ER
Positive 4 (16.7) 20 (83.3) 0.001*
Negative 19 (61.3) 12 (38.7)
PR
Positive 2 (10) 18 (20) <0.001*
Negative 21 (60) 14 (40)
HER-2
Positive 1 (100) 0 (0) 0.418
Negative 22 (40.7) 32 (59.3)
Ki-67
High 4 (36.4) 7 (63.6) 0.717
Low 8 (44.4) 10 (55.6)
Luminal A
Present 3 (18.8) 13 (81.3) 0.026*
Absent 20 (51.3) 19 (48.7)
Luminal B HER-2 negative
Present 1 (12.5) 7 (87.5) 0.120
Absent 22 (46.8) 25 (53.2)
Triple negative
Present 18 (60) 12 (40) 0.003*
Absent 5 (20) 20 (80)
*Statistically significant. TIL: Tumor infiltrating lymphocyte, PR: Progesterone receptor, ER: Estrogen 
receptor, NST: No special type.
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Of note, the wide range of c-MET positivity 
across different studies can be attributed to the different 
study populations as well as the significant variability in 
c-MET assessment and sampling techniques, usage 
of polyclonal versus monoclonal antibodies, different 
antibody clones, and variable scoring systems with 
variable cutoff values. The use of a monoclonal antibody, 
in our study, aimed to achieve better reproducibility. The 
choice of (SP44) clone against the intracellular domain 
of the receptor, stemmed from previous studies reporting 
that overexpression of this domain is far more common 
than the extracellular domain in breast cancer [29]. On 
a molecular level, results obtained with antibody SP44 
were relatively consistent with quantitative real-time 
PCR and Western blot analysis data [28]. The use of 
full-face sections rather than tru-cut biopsies stemmed 
from the previous reports of heterogeneous c-MET 
expression [30]. The relatively low cutoff (5% of tumor 
area) was according to previously suggested criteria and 
in view of the discordance between c-MET expression in 
tissue biopsy specimens using high immunohistochemical 
cutoff values and its expression in circulating tumor cells 
by flow cytometry in some studies [9], [26], [27].
The c-MET expression variation among 
different age groups (10-year intervals) was statistically 
significant, with the highest expression in extremes of 
age of our cohort (<30 and above 80 years). Patients 
younger than 40 years were previously found to exhibit 
c-MET overexpression at higher proportions, though 
the difference was not significant (p = 0.099) [3]. 
These findings can be partially explained and are in 
line with the emerging evidence that young age breast 
carcinoma (YABC) is rather a biologically distinct entity 
with possibly specific molecular profiles that may 
include c-MET expression [31]. YABC is more likely 
to exhibit poor differentiation/high grade, advanced 
stages, and hormone receptor negativity, all of which 
may confound its association with c-MET [32]. Elderly 
patients generally have a higher genetic damage burden 
due to aging and thus may have a greater chance of 
incurring c-MET aberrations and may also have other 
confounding variables such as advanced stage or high 
grade which was truly the case in our study. In contrast, 
many studies found no significant correlation with patient 
age at presentation and c-MET expression. These 
studies either had a narrower patient age range that did 
not include our extreme age groups 37-69 years or did 
not stratify patients into age groups in relation to c-MET 
expression [33], [34]. Similarly, studies that broadly 
stratified patients into broad dual categories did not show 
a significant association of c-MET with age which might 
miss out on the subtle variation among the finer 10 years 
interval age groups in our study [8], [35], [36].
The percentage of c-MET positive cases was 
greater in unifocal tumors; however, the relationship 
between c-MET expression and tumor multifocality was 
statistically insignificant. To the best of our knowledge, 
the relationship between tumor multifocality and c-MET 
expression in breast cancers has not been thoroughly 
investigated and our results are in contrast to the 
association of tumor multifocality and c-MET expression 
observed in other organs [37], [38], [39], [40]. Thus, 
larger-scale studies investigating multifocality and 
c-MET genetic aberrations, protein expression, and 
associated biomarker expression in breast carcinoma 
might add or dismiss similar insights.
Higher rates of c-MET expression were 
detected in larger sized tumors (T2, T3), though the 
relationship between tumor size (T status) and c-MET 
expression was statistically insignificant. Most studies 
similarly showed no significant association with 
c-MET expression [3], [8], [41]. However, a significant 
association between c-MET expression and large-
sized tumors was reported in a large sample size 
study (n = 924) and in a meta-analysis reviewing many 
immunohistochemical and non-immunohistochemical 
technique based studies [28], [42]. These apparently 
divergent results were reported comparing c-MET 
scores (high vs. low expression) rather than the 
incidence of expression per se and the high c-MET 
scores associated with smaller tumor sizes lead to a 
postulation that c-MET might have a more significant 
role in the early progression of smaller tumors [32].
The rate of positive c-MET expression was 
slightly higher in positive lymph node tumors, but the 
relationship between c-MET expression and lymph 
node status was statistically insignificant. A similar 
insignificant association was observed in the majority 
of encountered studies [3], [8], [27], [41]. However, a 
significant correlation with node involvement was found 
in a larger sized sample study using slightly higher 
cutoff value for c-MET expression [28]. On the contrary, 
Ho-Yen et al., 2014, by assessing scores rather than 
rates of expression found a significant relationship 
between high c-MET and node-negative tumors. 
The latter findings were explained by the high c-MET 
expressing basal-like tumors included in that study 
which have a tendency to metastasize more frequently 
through the hematogenous route and thus a higher 
incidence of node negativity [32].
The relationship between c-MET expression 
and anatomic stage (TNM) groups was statistically 
insignificant (p = 0.91). Similar findings were 
encountered [27], [42]. However, a significant association 
between c-MET expression and advanced stage was 
reported in studies having a large sample size or 
considering correlation with high score levels [28], [35]. 
In our study, highest rate of c-MET expression was 
detected in the most advanced prognostic Stage III; 
moreover, most of the prognostic Stage I tumors lacked 
c-MET expression and the relationship between c-MET 
expression and the prognostic stage groups was 
statistically highly significant. None of the compared 
studies assessing c-MET in breast cancer staged 
their cases according to the most recently published 
AJCC prognostic staging system. In our study, only the 
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associations of c-MET expression with the prognostic 
stages, incorporating the more important grade and 
hormone status, were statistically significant. In light of 
this result, the prognostic stage might provide a more 
reasonable predictor for expression and a helpful tool 
in patient selection for further studies.
As regard the tumor histotype, no significant 
association with the invasive duct carcinoma, NST 
histotype, and similar results were found in the many 
encountered studies [3], [8], [27], [28]. However, the 
rate of positive c-MET expression was significantly 
higher among the carcinoma with medullary features 
(p = 0.026). Yet, Ho-Yen et al., 2014, found that there 
is no correlation between c-MET scores and carcinoma 
with medullary features. This apparently divergent 
result might be due to their larger sample size and 
correlation with high c-MET scores [32]. Of note, most 
studies have not adequately addressed specifically the 
relationship between c-MET and the various histological 
subtypes, and comparison of c-MET expression was 
compared in invasive duct carcinoma NST versus 
minimally represented or an unspecified group of other 
histotypes [3], [8], [27], [28], [41].
The rate of c-MET positive expression was 
greater in the Grade III tumors versus Grade II tumors 
and this relation was statistically highly significant 
(p < 0.001). Similar results were approved in a meta-
analysis [42]. Other studies showed no statistically 
significant relationship between tumor grade and 
c-MET. Wang et al., 2018, study had only six cases to 
represent low-grade tumors (Grades I and II) (6% of 
total cases) which might have affected the statistical 
association with c-MET [8]. Constantinou et al., 2018, 
compared c-MET patients with well-differentiated 
tumors (Grade I) and moderately to poorly differentiated 
tumors (Grades II-III) [43]. Both Ren et al., 2016, 
and Constantinou et al., 2018, showed no significant 
association with tumor grade in exclusively sampled 
TNBC study population [3], [43]. The loss of a significant 
impact of the tumor grade status on c-MET expression 
in a certain group (triple negative cancers) in the later 
studies might indicate that the association with tumor 
grade is not in itself predictive of c-MET expression but 
rather it might be confounded by other variables (such 
as the receptor status) as will be further demonstrated 
by multivariate analysis in our study.
The rate of c-MET expression was significantly 
higher in tumors with high TILs. The relationship 
between c-MET expression and TILs in breast 
carcinomas has not been addressed in the previous 
studies; however, our results can be interpreted in view 
of the evidence in the literature for a role for c-MET 
signaling in promoting T cell recruitment by inducing an 
autocrine chemokine loop [44]. This is further backed 
up by emerging data describing a TIL prosurvival effect 
of c-MET signaling by suppressing Programmed Death 
Ligand-1; an immunomodulatory molecule that triggers 
apoptosis of TILs, and dual inhibition of both molecules 
in experimental models synergistically enhances the 
tumor suppressing abilities [45].
The relationship between perineural invasion 
and c-MET expression was statistically insignificant; 
however, our results are in line with findings in other 
organ neoplasms as colorectal carcinoma and 
melanomas [46], [47]. This relation was not tackled in 
breast carcinoma, and in view of the few cases with 
perineural invasion in our study (n = 5), this relation 
merits further investigation.
The relationship between lymphovascular 
invasion and c-MET expression was statistically 
insignificant (p = 0.867). Similarly, there was no significant 
association between lymphovascular invasion with c-MET 
expression or its levels in many studies [8], [32], [43].
The rate of c-MET expression was significantly 
higher in ER-negative and PR-negative tumors and 
the relationship between hormone receptor status and 
c-MET expression was statistically highly significant 
(p = 0.001). Similar results were obtained in a large 
sample study [28]. However, other studies showed no 
significant association with the hormone receptor status 
by investigating a different c-MET antibody clone and 
patients receiving neoadjuvant therapy before c-MET 
assessment or by considering score levels of c-MET 
(high/low) expression [27], [35].
The relationship between Ki-67 and c-MET 
expression was statistically insignificant (p = 0.717). 
A similar insignificant association was reported using 
Ki-67 cutoff value (14%) close to ours (20%) [3]. 
Significant association of c-MET with Ki-67 behavior 
using cutoff values for Ki-67 higher than our study 
(>30%) was also described [43].
There was a significant variation among 
molecular subtypes in c-MET expression with significantly 
higher rate c-MET negativity in Luminal A subtype versus 
other subtypes and a higher rate of c-MET positivity 
among the triple negative subtype. Similar findings were 
found by Kim et al., 2014, and are in keeping with the 
Ho-Yen et al., 2015, review which showed a significant 
association of basal subgroup of triple negative tumors 
with c-MET expression [28], [41]. In contrast, Koh et al., 
2014, found that c-MET positive tumors were less likely 
to have the triple negative subtype than c-MET negative 
ones. The latter study used a different antibody clone to 
asses c-MET, had a fewer number (n = 23) as well as a 
smaller proportion (18%) of triple negative cases than 
our study and the patients were subjected to neoadjuvant 
therapy before c-MET evaluation which may alter its 
assessment [27].
The only independent predictors of c-MET were 
high TILs and negative PR status and all other variables 
were excluded by forward conditioned regression. 
Similarly, Carracedo et al., 2009, in a fluorescence 
in situ hybridization/immunohistochemical study showed 
that negativity for PR significantly correlated with c-MET 
expression in a multivariate analysis [48].
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Conclusion
Tight clinicopathological correlation is needed 
in future clinical trials to identify clinically relevant 
score cutoff values for c-MET expression that can be 
translated into beneficial clinical responses. When 
considering patients for anti-c-MET clinical trials, 
patients at extremes of age (<30 and above 80 years), 
and prognostic stage rather than the anatomic stage 
groups, Grade III tumors, carcinoma with medullary 
features, tumors with high TILs, and TNBCs are more 
likely to express c-MET and as such, they are suitable 
candidates. By excluding confounding factors, high 
TILs and PR negative status were especially important 
and independently significant in a multivariate analysis.
Tumor multifocality, tumor size, lymph node 
status, anatomic stage, lymphovascular or perineural 
invasion, and Ki-67 expression are less likely to reflect 
c-MET status. Many factors that failed to demonstrate a 
significant relation with c-MET, in our study, were either 
poorly represented (such as HER-2 positive tumors) or 
have been shown to significantly correlate with c-MET 
in other studies or in other organ cancers and as such 
merit further investigation in large scale studies.
To the best of our knowledge, tumors at 
extremes of age, carcinoma with medullary features, and 
prognostic stage were not previously recognized in the 
literature as significant predictors of c-MET expression. 
Moreover, high TILs relation with c-MET expression in 
breast carcinoma has never been addressed. The latter 
relation retains its weight in multivariate analysis and 
merits special consideration in the light of emerging 
back up data depicting a prosurvival effect of c-MET on 
TILs, as such, its utility may surpass patient selection 
to inspire a whole new paradigm in future studies and 
clinical trials.
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